Why Europe now demands a different approach to medical digital products
Building medical digital products in the European Union is no longer just a software challenge. It is a regulatory, clinical, data, and market access challenge that starts long before submission. Across Europe, companies developing software as a medical device, AI-enabled decision support, remote monitoring platforms, companion apps, and digital therapeutics are operating in a much stricter environment, where the product itself is only one part of the equation.
The real differentiator is whether those medical digital products are supported by clear intended use, structured technical documentation, traceable development, clinical evidence, cybersecurity readiness, and a quality system that can withstand regulatory review. Recent European industry events show exactly how central these topics have become.
The MedTech Forum 2025 and 2026 programs highlight AI-enabled technologies, market access, funding, and access challenges across digital health, while the Medical Device Software Development Summit Europe has put regulatory submissions, AI software documentation, cybersecurity, and legacy device updates at the center of discussion.
That shift matters because medical digital products are now being judged not only by innovation potential, but by how well they fit the reality of EU MDR and broader European health system expectations. The European Digital HealthTech Conference 2025 framed the European Health Data Space as a catalyst for innovation, but also made it clear that new opportunities come with demands around standards, security, interoperability, trust, adoption, and secondary use of health data. In other words, Europe is still a highly attractive market for medical digital products, but only for companies that can connect innovation with regulatory discipline and data governance from day one.
Real companies show where the medical digital products market is going
The strongest way to understand where the market is moving is to look at real companies already building regulated medical digital products in Europe. Huma is one of the clearest examples of platform-level maturity. The company announced EU MDR Class IIb approval for its configurable, multi-condition Software as a Medical Device platform, describing it as the only disease-agnostic platform of its kind at that certification level and noting that its regulatory assessment included evidence from more than 20 peer-reviewed publications and studies.
That matters because it shows that medical digital products are moving beyond single-use apps toward reusable regulated platforms that can support faster scaling when the evidence, quality, and regulatory model are strong enough.
Brainomix is another strong example of how medical digital products are becoming deeply embedded in clinical workflows rather than sitting at the edge of care. Its Brainomix 360 Stroke platform is a CE-marked collection of AI-driven tools for stroke assessment, and the company states that its individual modules, ASPECTS, e CTA, and e CTP are CE-marked Class IIa medical devices intended for clinical decision support in acute ischemic stroke imaging. This is the kind of product category Europe is increasingly rewarding: not generic wellness software, but high-impact medical digital products that directly support treatment decisions in time-critical care pathways.
Quibim provides a useful imaging AI example on the diagnostics side. The company states that QP Prostate secured CE marking as a Class IIb device and was one of the first AI products approved under the new MDR framework. That is an important signal for the future of medical digital products in Europe, because it shows that higher-risk AI tools can get through the system when they are built with sufficient regulatory rigor and product specificity. It also shows how imaging, AI, and regulated productization are converging into a much more serious commercial category than the market often assumes.
Legit.Health shows what this looks like in dermatology. The company describes its platform as a CE-marked medical device, says it is ISO 13485 compliant for medical device software development and maintenance, and notes published clinical evidence from hospitals, including University Hospital of Torrejón and Cruces and Basurto Hospitals in Spain. That combination of CE marking, quality alignment, and hospital-backed validation is exactly what makes medical digital products credible in Europe.
It is no longer enough to claim AI capability. European buyers, partners, and regulators increasingly expect real clinical grounding behind medical digital products before they scale.
Kaia Health is another real example worth using because it shows that medical digital products in Europe do not need to sit only in hospital imaging or clinician-facing software. Kaia’s COPD pulmonary rehabilitation app was described by the company as CE marked in Europe as a Class I medical device, and the company positioned it as an evidence-backed digital therapeutic designed to extend access to pulmonary rehabilitation in patients’ homes. That is important because it reflects a broader trend in European medical digital products toward structured home-based care, digital rehabilitation, and scalable non-pharmacological interventions that still require evidence, compliance, and clinical framing.
The conference topics shaping medical digital products in Europe
What makes these examples more compelling is that they align closely with what conference organizers and industry leaders are actually discussing. The European Digital HealthTech Conference 2025 focused on the European Health Data Space and explicitly connected it to health data collection, standardisation, organisation, secondary use for research and innovation, and the need to build trustworthy digital health solutions that patients and healthcare professionals will actually adopt. For companies building medical digital products, this is a major signal that success in Europe will increasingly depend on interoperability, trust, and evidence-based use of data, not just on product design alone.
At the Medical Device Software Development Summit Europe, the language is even more direct. The event positioned itself around software development, quality assurance, regulatory affairs, and product teams working together to keep pace with evolving global regulatory frameworks, AI and machine learning enabled software, cybersecurity, and agile methodologies. It specifically spotlighted documentation strategies for AI-enabled medical device software, automation tools that create feedback loops across development, data validation, and cleansing for AI training datasets, and ways to manage updates to legacy devices. Those are not side issues. They are now core operating requirements for teams building medical digital products that need to survive regulatory review and remain maintainable after launch.
The MedTech Forum adds the business layer to that picture. Official program material for 2025 and 2026 highlights AI in Europe’s complex healthcare environment, revenue and market access strategy, and funding and access challenges across diagnostics, digital health, and AI-enabled technologies.
That matters because the future of medical digital products in Europe is not just about approval. It is also about reimbursement logic, adoption pathways, health system fit, and whether a product can create enough clinical and economic value to be scaled sustainably.
What this means for companies building medical digital products
The practical lesson is straightforward. European success now belongs to companies that build medical digital products with regulatory, clinical, technical, and commercial alignment from the start. The examples above show that the market is rewarding products with a clear intended use, a defensible quality framework, credible evidence generation, and a realistic understanding of how the product will be implemented in real care environments.
The conference agenda across Europe reinforces the same message from another angle: data governance, AI documentation, cybersecurity, interoperability, trust, and market access are now inseparable from product strategy.
For that reason, companies cannot treat medical digital products as ordinary software with a regulatory layer added later. In the European Union, the strongest medical digital products are being built as regulated products from the beginning. They are designed for evidence generation, documented for scrutiny, maintained through structured quality processes, and positioned for real adoption in clinics, hospitals, and home care pathways. That is the level the market is moving toward, and it is the standard that will separate durable MedTech businesses from short-lived digital health experiments.
Europe is still one of the most important growth markets for medical digital products, but it is no longer a place where speed alone wins. The most credible companies are showing that progress comes from pairing product innovation with regulatory depth, clinical evidence, data trust, and implementation realism.
Huma, Brainomix, Quibim, Legit.Health and Kaia Health each illustrate a different part of that story, while current conference agendas across Europe confirm that the conversation has shifted toward the full lifecycle of medical digital products, from AI documentation and interoperability to reimbursement and adoption.